Background-Sarcomere protein mutations in hypertrophic cardiomyopathy induce subtle cardiac structural changes before the development of left ventricular hypertrophy (LVH). We have proposed that myocardial crypts are part of this phenotype and independently associated with the presence of sarcomere gene mutations. We tested this hypothesis in genetic hypertrophic cardiomyopathy pre-LVH (genotype positive, LVH negative [G+LVH−]). Methods and Results-A multicenter case-control study investigated crypts and 22 other cardiovascular magnetic resonance parameters in subclinical hypertrophic cardiomyopathy to determine their strength of association with sarcomere gene mutation carriage. The G+LVH− sample (n=73) was 29±13 years old and 51% were men. Crypts were related to the presence of sarcomere mutations (for ≥1 crypt, β=2.5; 95% confidence interval [CI], 0.5-4.4; P=0.014 and for ≥2 crypts, β=3.0; 95% CI, 0.8-7.9; P=0.004). In combination with 3 other parameters: anterior mitral valve leaflet elongation (β=2.1; 95% CI, 1.7-3.1; P<0.001), abnormal LV apical trabeculae (β=1.6; 95% CI, 0.8-2.5; P<0.001), and smaller LV end-systolic volumes (β=1.4; 95% CI, 0.5-2.3; P=0.001), multiple crypts indicated the presence of sarcomere gene mutations with 80% accuracy and an area under the curve of 0.85 (95% CI, 0.8-0.9). In this G+LVH− population, cardiac myosin-binding protein C mutation carriers had twice the prevalence of crypts when compared with the other combined mutations (47 versus 23%; odds ratio, 2.9; 95% CI, 1.1-7.9; P=0.045). Conclusions-The subclinical hypertrophic cardiomyopathy phenotype measured by cardiovascular magnetic resonance in a multicenter environment and consisting of crypts (particularly multiple), anterior mitral valve leaflet elongation, abnormal trabeculae, and smaller LV systolic cavity is indicative of the presence of sarcomere gene mutations and highlights the need for further study. (Circ Cardiovasc Imaging. 2014;7:863-871.)
H ypertrophic cardiomyopathy (HCM) is a common hereditable heart disease with a population prevalence of 1 in 500 and affected individuals are at risk of adverse outcomes, including sudden cardiac death 1 and progression to heart failure. HCM is frequently caused by dominant mutations in sarcomere protein genes, present in 30% to 60% of patients. 2 Because of the growing availability of advanced imaging, myocardial architectural abnormalities can be investigated in subclinical HCM sarcomere gene mutation carriers before the development of left ventricular hypertrophy (genotype positive, left ventricular hypertrophy negative [G+LVH−]). Initially reported separately and in single-center studies, some of the cardiac abnormalities of subclinical HCM (myocardial crypts, 3 anterior mitral valve leaflet [AMVL] elongation, 4 abnormal LV apical trabeculae, 5 and smaller LV systolic cavity) 6 have recently been shown to cluster into an identifiable phenotype by cardiovascular magnetic resonance (CMR) 5 with emerging data suggesting that crypts may be an important morphological feature in genetic HCM. 3, 7 Here, we present a multicenter study exploring crypts and other morphological features in subclinical HCM to identify the parameters that are most strongly indicative of the presence of a sarcomere gene mutation before the development of LVH.
Methods

Investigator Consortium
A multicenter collaboration established the largest cohort to date, of genotyped, LVH− HCM sarcomere gene mutation carriers (n=73) with comprehensive CMR imaging. Using a matched case-control design, G+LVH− and healthy controls underwent CMR and electrocardiographic characterization. Twenty-four CMR parameters (2 of which related to crypts) were explored for potential association with the presence of sarcomere mutations.
The 12 centers included University College London (UCL, The Heart Hospital) and a further 11 US centers forming part of the HCMNet HCM clinical network (Note I in the Data Supplement). The UK component of the G+LVH− population (n=39) has been described previously. 5 
Study Population
Inclusion and exclusion criteria for patients and healthy controls were defined a priori. Inclusion criteria for G+LVH− were (1) maximal LV wall thickness <13 mm by CMR in subjects ≥18 years; maximal LV wall thickness <12 mm or z score <2.5 by echocardiography in subjects <18 years 8 ; (2) LV mass within the normal range relative to body surface area (BSA), age and sex; (3) sinus rhythm, no LVH, and no pathological Q waves/T-wave inversion on 12-lead ECG; (4) no causes of secondary LVH such as valve disease, or systemic hypertension that was defined as systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg, or the use of medical therapy for hypertension. Controls had no other medical conditions and were healthy volunteers or relatives without the sarcomere gene mutation. Controls were recruited from 5 centers and matched to unrelated G+LVH− patients on the basis of age (±8 years), sex, BSA (±10%), and ethnicity in a 1:1 ratio. Controls had no personal history of cardiovascular disease, unexplained syncope or systemic hypertension, and a normal physical examination. Exclusion criteria for all participants were the presence of conventional contraindications for CMR, claustrophobia, and a high arrhythmogenic burden (eg, atrial fibrillation, frequent ectopics) that precluded good cine acquisitions.
Electrocardiography
Standard 12-lead electrocardiography was performed in the supine position during quiet respiration in all recruited participants. LVH was evaluated with the Romhilt-Estes criteria 9, 10 (Table I in the Data  Supplement) . Within the respective institutions electrocardiograms were analyzed by experienced observers, blinded to clinical information. No G+LVH− had pathological Q waves (defined as duration >40 ms or depth >⅓ R wave in ≥2 leads) or T-wave inversion (defined as ≥3 mm in ≥2 leads).
Genetic Screening
All 73 G+LVH− underwent genetic testing to identify DNA sequence variants in sarcomere genes. Nonsynonymous pathogenic and likely pathogenic variants were selected on frequency (<0.5% based on the 1000 Genomes Database), 11 evolutionary conservation, previous reports in the literature, putative functional consequence, 12 and cosegregation in the family, when available. G+LVH− were classified as carrying a mutation in one of the following sarcomere genes: 13 tropomyosin 1 α-chain (TPM1); actin, α-cardiac muscle 1 (ACTC1); myosin-binding protein C, cardiac type (MYBPC3); myosin heavy chain, cardiac muscle beta isoform (MYH7); myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MYL2); myosin light polypeptide 3 (MYL3); troponin T, cardiac muscle (TNNT2); and troponin I, cardiac muscle (TNNI3).
Cardiovascular Magnetic Resonance
CMR consisting of standard clinical scans was performed on all recruited patients and controls using 1.5-and 3-Tesla magnets from different manufacturers (Avanto/Tim Trio, Siemens Medical Solutions, Erlangen, Germany; Signa Excite; General Electric Medical Systems, Waukesha, WI, USA; Achieva, Philips, Amsterdam, The Netherlands). Retrospectively electrocardiographically gated, breathheld, long-and short-axis cine images were acquired using a steadystate free precession sequence. Scan parameters used for Siemens, General Electric and Philips scanners are provided in Table II in Their complexity cannot be efficiently summarized using traditional Euclidean geometry. Fractal geometry is based on a mathematical construct and has the ability to measure complex objects. Real-world biology and some naturally occurring images may also be complex and exhibit self-similarity within a finite range. As an illustration, perfect points have a topological dimension (TD) of 0, straight lines or smooth regular curves have a TD of 1, flat planes have a TD of 2. Biological images tend to have nonlinear features of dimension >1: in this case endocardial contours may be regarded as nonlinear quasi-fractal forms observed on the 2-dimensional imaging plane. Their fractal dimension (FD) is therefore any noninteger value between 1 and 2. B, Top, Three exemplar slices from a genotype positive, left ventricular hypertrophy negative (G+LVH−) with corresponding FD. Bottom, Slices from a control.
LV volumes, ejection fraction, and LV mass were determined according to the standardized CMR methods 14 at The Heart Hospital and at the National Institutes of Health Clinical Center, with the latter serving as the CMR core laboratory for HCMNet. Specifically, LV end-systolic volume (LVESV; mL) was measured from endocardial tracings applied to the sequential short-axis cines covering the entire ventricle. To adjust for participant sex and age (wide range in this study), measured BSA-indexed LVESVs were converted to normalized ratios (LVESVi R ; Note II in the Data Supplement). LV wall thickness was calculated per segment on end-diastolic and endsystolic short-axis cine frames. The structure of the LV was evaluated for crypts by a cardiologist with >3 years of experience in CMR (G.C.). In the absence of a general consensus on the definition of a crypt, we defined a myocardial crypt as the presence of a focal myocardial defect in diastole, showing at least partial systolic obliteration and having a depth ≥50% the thickness of the adjacent myocardium. Anything less than this (eg, a partial crypt, <50% thickness) was not counted. Standard long-axis cines (with cross-validation on the shortaxis cines, where appropriate) were used to locate crypts without the modified 2-chamber view. In 2 equivocal cases the presence or absence of crypts was resolved by consensus. Two readers (G.C. and G.F.) blinded to clinical diagnosis evaluated 50 CMR scans pertaining to a mix of cases and controls for calculation of the intra-and interobserver variability in crypt rulings (scored as absent, single or multiple crypts). Raw AMVL length was estimated using the method described by Maron et al 4 and adjusted for body size by dividing by BSA. Trabeculation was quantified using the technique of fractal analysis. The theory behind the technique is described in Figure 1 . Experiments to test dependency of the fractal dimension (FD) on slice thickness and magnetic field strength are described in Note III in the Data Supplement. Briefly, FD for an endocardial contour (a 2-dimensional object) is a noninteger value between 1 (least complex) and 2 (most complex) such that previously published 5, 15 indices for LV maximal apical FD (FD MaxApical ) in healthy controls were 1.199±0.05, and in LV noncompaction, 1.392±0.01. Validation and repeatability experiments for the method have been published previously. 5, 15 Distribution of data was assessed on histograms and using Shapiro-Wilk test. Categorical variables were compared by χ 2 or Fisher exact tests. Normally distributed continuous variables pertaining to patients and controls were compared using paired t test. Univariable conditional logistic regression models were created to estimate the strength of the association between potential predictors and HCM sarcomere gene mutation carriage. These analyses were repeated to account for family relations among G+LVH− after randomly retaining only 1 subject per family (Tables III and IV in the Data  Supplement) . On account of complete separation of the highly significant variable multiple crypts conditional logistic regression was not feasible so we performed a Firth-type 16 unconditional matched logistic regression as per Heinze et al. 17 In this model, significant factors from the univariable analysis were removed one at a time using backward elimination, starting with the factor that had the largest P value, until all remaining factors had a 2-sided P value <0.05. In addition, a variance inflation factor of <3 excluded near-multicollinearity. β-Coefficients of model variables were used to compile the prediction rule in this case-control population through an integer score system that assigned a weight based on the magnitude of the coefficient. For the optimal model, we determined the rate of correct classification, that is, accuracy, using leave-one-out cross-validation 18 and by constructing contingency tables. Optimal threshold values for AMVL length, FD MaxApical , and LVESVi R were calculated as the Youden Index derived from the area under the receiver operating characteristics curves. A 2 -sided P value <0.05 was considered significant. Cohen κ was used to compare variability of crypt rulings between readers.
Results
Clinical and demographic information for G+LVH− and controls are provided in Table 1 and provenance information in relation to the individual HCMNet center is provided in Note I in the Data Supplement. Of the 73 matched controls, 71 were healthy volunteers and 2 were genotypenegative healthy relatives of HCM probands, the latter with confirmed pathological sarcomere mutations. Children and adolescents (<18 years) comprised 19% of the population. The 73 G+LVH− patients were all genotyped and they pertained to 62 unrelated families expressed a total of 44 unique sarcomere gene mutation variants. Prevalence of sarcomere protein gene mutations is shown in Table 1 and a full listing of variants provided in Table I in the Data Supplement. Of the 24 CMR parameters studied, 11 had significant association with carrier status on univariable logistic regression ( Table 2) . Differences in AMVL length between G+LVH− and controls persisted for the body size-adjusted variable, and BSA-adjusted AMVL length retained association with genetic status on univariable logistic regression. Twenty-four G+LVH− (33% of 73; Figure 2 ) and 2 controls (3% of 73) had ≥1 myocardial crypt. Fourteen G+LVH− (19%) and no controls (0%) had ≥2 crypts. For G+LVH− 2 crypts were counted in 5 participants; 3 crypts in 8; and 4 crypts in 1. Compared with the other combined mutations in G+LVH− (Figure 3) , MYBPC3 mutation carriers had twice the prevalence of crypts (23% versus 47%, respectively; odds ratio, 2.88; 95% confidence interval, 1.05-7.91; P=0.045) and were less likely to demonstrate LV systolic cavity reduction (LVESVi R <0.803 in 61% of non-MYBPC3 versus 33% in MYBPC3; odds ratio, 0.33; 95% confidence interval, 0.12-0.87; P=0.032). The relationship between specific mutation variants and crypt prevalence is illustrated in Figure 4 . Reproducibility for crypt rulings was high (intraobserver κ, 0.92; interobserver κ, 0.85). Derived cutoffs for model variables are also shown. Based on this model a combined prediction score of ≥3 denotes G+LVH− status. AMVL indicates anterior mitral valve leaflet; CI, confidence interval; FD MaxApical , maximal apical fractal dimension; G+LVH−, genotype positive, left ventricular hypertrophy negative; LVESVi R , BSA-indexed left ventricular end-systolic volume corrected for age and sex; and OR, odds ratio.
Table 3. Final Model by Logistic Regression Using Firth's Penalized Maximum Likelihood Method
*Model parameters entered as categorical (binary) predictors derived from Youden-based cutoffs. The final multivariable model consisting of 4 key imaging markers is summarized in Table 3 and Figure 5 . The variable ≥1 crypt was also associated with the presence of sarcomere mutations (see Table V in the Data Supplement) but multiple crypts (≥2) provided the better model (leaveone-out cross-validation model accuracy of 79%). For the prediction rule applied to this case-control population, multiple crypts and elongated AMVL were each assigned a score of 2, whereas increased LV apical trabeculation and smaller LVESVi R were each assigned a score of 1. A combined score of ≥3 represented the optimal cutoff for the prediction rule, achieving 79.5% agreement with genetic diagnosis in this case-control population (positive predictive value, 82.1%; 95% confidence interval, 70.4-90.0; negative predictive value, 77.2%; 95% confidence interval, 66.1-85.6).
Discussion
Before the development of LVH, HCM sarcomere gene mutation carriers exhibit a subclinical cardiac phenotype that is detectable by CMR in a multicenter environment (3 scanner manufactures, 2 MR field strengths). The combined presence of ≥2 myocardial crypts, ≥21 mm AMVL length, increased LV apical trabecular complexity with FD MaxApical ≥1.241, and smaller LV end-systolic volume with LVES-Vi R <0.803 is indicative of a subclinical HCM phenotype in sarcomere gene mutation carriers. Of these, myocardial crypts and AMVL elongation emerge as the 2 parameters that most strongly associate with the presence of sarcomere gene mutations. Our initial observations also suggest that MYBPC3 mutation carriers have a 2-fold prevalence of crypts and less LV systolic cavity reduction compared with the other combined mutations, intriguing preliminary findings that are hypothesis-generating and merit evaluation in larger future studies.
American and European guidelines on family screening for HCM 19, 20 recommend genotyping if a pathogenic mutation has been identified in the family. However, many probands do not have definitive results with genetic testing 21, 22 and such data cannot be used to identify at-risk relatives in family screening. 23 Further prospective work is needed to explore the added value of CMR imaging rules in these situations.
The definition of myocardial crypts is not yet settled, making comparisons of prevalence between studies difficult. Single myocardial crypts do occur in the non-HCM population, with prevalences of 2.2% by Srichai et al, 24 6% by Brouwer et al, 7 7% by Johansson et al, 25 8.7% by Petryka et al, 26 and in this study, 2.7%. However, Johansson et al 25 and our study showed how multiple crypts remain an unusual finding in truly healthy hearts (0.8% and 0%, respectively). Erol et al. 27 reported a slightly higher prevalence of multiple crypts (49 of 2093 participants, 2%) but they used contrast computed tomography, acquired a 3-dimensional whole-heart data set, and studied clinically referred cardiac patients that included preoperative evaluation scans and assessment of congenital heart disease. In G+LVH− HCM, multiple myocardial crypts are more prevalent than in the general population: ≥2 crypts were identified in 58% of G+LVH− by Maron et al 28 (11 of 31) and in 19% of our G+LVH−. However, multiple crypts have also been observed by Brouwer et al 7 in 16% (9 of 57) of patients with nonischemic (non-HCM) cardiomyopathy, suggesting that crypts in different contexts may have alternative significance. 29 Previous studies 4, 5 have reported on the finding of abnormally elongated AMVL in G+LVH−. Here, we show how differences in AMVL length persist even after adjustment for body size. After multiple myocardial crypts, AMVL elongation has the second strongest association with the presence of sarcomere gene mutations. The finding of abnormal trabecular architecture in the apical half of the LV, already described in the UK G+LVH− cohort, 5 survived in this multicenter environment where FD MaxApical emerged as the third strongest independent predictor. The mechanism for this remains unclear but our hypothesis is that the hypertrabeculation, like the crypts, represents persistence of the embryological form into adulthood (a neoteny). Other interesting possibilities for the trabecular changes have also been previously discussed. 5 The finding of smaller LV systolic cavities in G+LVH− compared with controls similarly accords with published data: compared with controls, G+LVH− had ≈10 mL smaller LVESV 30 by CMR and higher ejection fraction 31 by echocardiography (71±6 versus 64±5; P<0.0001) in the studies by Ho et al. Likewise, De et al 32 showed significantly higher ejection fraction (61±4 versus 58±4) by echocardiography in G+LVH− compared with controls.
Limitations are that some of the G+LVH− patients were related but we show how findings are independent of the degree of relatedness (see Note IV and Tables IV and V in the Data Supplement). Diastolic function and T1 mapping differences 30, 31 have been observed in subclinical HCM but were not studied here. Future studies should attempt to revisit these parameters systematically and using standardized protocols to build on our present findings. External validation of the CMR imaging rule will help evaluate the fitness of the model and the generalizability of these first multicenter results, independent of any selection bias that may potentially be confounding participant selection in this study. Such validation would also be important to further test the performance of the model and to ensure that the rule is not driven by idiosyncracies in the 73 matched pairs. We used 3 long-axis views, cross-referenced against the short-axis images where appropriate but no modified views for crypt detection. Further work is needed to understand the embryological origins of crypts, the role of both crypts and the other features, in HCM that has not been genetically defined, and the predictive power of the subclinical phenotype on both, future LVH development, and clinical outcomes.
In conclusion, the subclinical HCM phenotype measured by CMR in a multicenter environment, and consisting of crypts (particularly multiple), AMVL elongation, abnormal trabeculae, and smaller LV systolic cavity, is indicative of the presence of sarcomere gene mutations and highlights the need for further study.
